Search
Corbus Pharmaceuticals Holdings Inc
CRBPAdd to Watchlist
9.250USD
+0.180+1.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
171.38MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.98%
5 Days
+12.12%
1 Month
+22.68%
6 Months
+17.53%
Year to Date
+13.64%
1 Year
+19.35%
Key Figures
9.140Open
9.490High
444.96KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.53%Turnover Ratio
9.070Prev. Close
9.080Low
3.12MTurnover
LossP/E Static
1.10P/B
0.00%Div Yield TTM
-59.44%ROA
20.56052wk High
0.99Volume Ratio
-40.21MNet Profit
17.61MShares
-5.7339EPS TTM
2.59Beta
-66.70%ROE
6.72052wk Low
4.52%Amplitude
--Gross Margin
171.38MMarket Cap
5.21Reward/Risk
4.40%Risk Rate
TradingKey Stock Score of Corbus Pharmaceuticals Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Corbus Pharmaceuticals Holdings Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 37.33.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Corbus Pharmaceuticals Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Corbus Pharmaceuticals Holdings Inc Highlights
StrengthsRisks
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -1.61, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 13.43M shares, decreasing 15.70% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 61.59K shares of this stock.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
37.333
Target Price
+315.74%
Upside Space
Corbus Pharmaceuticals Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Corbus Pharmaceuticals Holdings Inc Info
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Ticker SymbolCRBP
CompanyCorbus Pharmaceuticals Holdings Inc
CEOCohen (Yuval)
Websitehttps://www.corbuspharma.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52823.700
-18.800 (-0.04%)
29609.100
+297.700 (+1.02%)
7497.800
+26.300 (+0.35%)
14950.000
+147.000 (+0.99%)
69466.000
+1318.000 (+1.93%)
6370.000
+17.200 (+0.27%)
68.613
+0.269 (+0.39%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4179.480
+57.570 (+1.40%)
FAQs
What is the current price of Corbus Pharmaceuticals Holdings Inc (CRBP)?
The current price of Corbus Pharmaceuticals Holdings Inc (CRBP) is 9.25.
What is the symbol of Corbus Pharmaceuticals Holdings Inc?
The ticker symbol of Corbus Pharmaceuticals Holdings Inc is CRBP.
What is the 52-week high of Corbus Pharmaceuticals Holdings Inc?
The 52-week high of Corbus Pharmaceuticals Holdings Inc is 20.56.
What is the 52-week low of Corbus Pharmaceuticals Holdings Inc?
The 52-week low of Corbus Pharmaceuticals Holdings Inc is 6.72.
What is the market capitalization of Corbus Pharmaceuticals Holdings Inc?
The market capitalization of Corbus Pharmaceuticals Holdings Inc is 162.91M.
Is Corbus Pharmaceuticals Holdings Inc (CRBP) currently rated as Buy, Hold, or Sell?
According to analysts, Corbus Pharmaceuticals Holdings Inc (CRBP) has an overall rating of STRONG BUY, with a price target of 37.33.
What is the Earnings Per Share (EPS TTM) of Corbus Pharmaceuticals Holdings Inc (CRBP)?
The Earnings Per Share (EPS TTM) of Corbus Pharmaceuticals Holdings Inc (CRBP) is -5.90.